Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis.
about
Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysisEfavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsTrends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational databaseHIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based SchemesCause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral TherapyModeling Outcomes of First-Line Antiretroviral Therapy and Rate of CD4 Counts Change among a Cohort of HIV/AIDS Patients in Ethiopia: A Retrospective Cohort StudyEfavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individualsThe Role of ARV Associated Adverse Drug Reactions in Influencing Adherence Among HIV-Infected Individuals: A Systematic Review and Qualitative Meta-Synthesis.Developments in HIV-1 immunotherapy and therapeutic vaccination.Performance evaluation of BD FACSPresto™ point of care CD4 analyzer to enumerate CD4 counts for monitoring HIV infected individuals in NigeriaArtemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan childrenPharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjectsSafety and effectiveness of combination antiretroviral therapy during the first year of treatment in HIV-1 infected Rwandan children: a prospective studyOnce-Daily, Single-Tablet Regimens For the Treatment of HIV-1 InfectionPlasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial)An assessment of adverse drug reactions among HIV positive patients receiving antiretroviral treatment in South Africa.Inhibition of major drug metabolizing CYPs by common herbal medicines used by HIV/AIDS patients in Africa-- implications for herb-drug interactions.Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapyAntiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study.The Influence of Medication Attitudes on Utilization of Antiretroviral Therapy (ART) in Indonesian PrisonsCase report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation.Improved survival in HIV treatment programmes in AsiaClinical Evaluation of the BD FACSPresto™ Near-Patient CD4 Counter in KenyaDolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic ReviewSelf-Reported Side Effects and Adherence to Antiretroviral Therapy in HIV-Infected Pregnant Women under Option B+: A Prospective StudyRisk factors associated with sexually transmitted infections among HIV infected men who have sex with men.An analysis of drug resistance among people living with HIV/AIDS in Shanghai, ChinaMulticenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to preventionEFV/FTC/TDF-associated hepatotoxicity: a case report and review.Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South AfricaClinical analysis of HIV/AIDS patients with drug eruption in Yunnan, China.Management of BU-HIV co-infection.Efavirenz-based antiretroviral therapy versus nevirapine-including regimens for prevention of mother-to-child transmission of HIV option B plus in resource-limited settings: is there anything missing?Developments in early diagnosis and therapy of HIV infection in newborns.Advances in the Pharmacogenomics of Adverse Drug Reactions.Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children.
P2860
Q27021762-E3227DA4-DBFE-4383-9AA5-0C7A73B0BEDCQ28081266-33F1FA3B-01D4-43C0-9679-CA7E2249BFD6Q28542731-7BB4BE62-057F-48F9-8C72-CC8199C07B36Q28551618-EBA80ED5-C0AA-4B51-BDC3-24A66A5E5FC6Q28553516-86EDB15F-0FC2-4267-8BF8-BC6E07775044Q28555157-EDF358E5-351F-464C-A0A6-96DB5694DE61Q30240127-1ACC827A-855E-4732-9AAB-EB242D975C5AQ30245495-DB859C74-C248-433D-BC14-023DFE19E8DCQ30364312-9C4B4F67-B69D-4EEE-B361-36EBFFCED7C1Q32112299-CB803885-E5B3-4722-87E5-273EF478F2AAQ34137766-B5BB77A8-628D-41E7-B40B-23542AF5BAA0Q34306474-CDC60D4A-AD35-4CDB-8868-2544D0CCDF2AQ34445856-F4189B3A-BC43-48C9-8391-428C7D59F026Q34976284-B61AFA64-0D75-4BD7-A799-A48587BD31B6Q35114865-E62434A4-E791-4B07-91FC-6AFE65EB1592Q35147717-EAA1E0EC-242D-4945-977E-07BDA47B43EFQ35162440-4D976328-D3B7-4DE5-9A3F-89297769F051Q35205900-F67EDF90-9FFF-4145-9184-C3CB708EA83DQ35547048-C79A314D-FAC3-44F1-AACF-8E3559D2EEE7Q35717749-57BE8878-7103-4DC6-8A62-77CCCF6A13CDQ35785892-5CAD8A57-82AC-4409-B137-60DA6BDA7DC9Q35910664-DC25EC3D-69FA-4FF8-9D83-36A955C16ADFQ35951760-355B5097-B777-4E9F-A0E9-76C3965ED62AQ36092410-2F615A99-3F06-45F5-91F6-8C101B83DD0FQ36162401-0489E420-BDD7-405C-9BE5-8C7DDB9E147BQ36167659-EBB1FFD7-CD22-4D10-9E3D-0F92796577BAQ36270155-8975726D-6E1C-4B45-8D12-1D56D27E340CQ36277181-3EB5FAF7-D9F6-4164-9EE7-4D6CE1C39A5BQ36286145-2D1B62F7-FB88-4D36-A365-9828DCED6092Q36426953-31849970-2E0E-4BB6-97C3-01BC8CCCD5F9Q36501872-BAD02940-C6CE-4A79-ACDB-2276D742847FQ37071435-286BCEB0-C39B-4F3F-A603-177825B7D0EEQ37139458-38F76866-6A99-4746-841B-235B12CF441CQ37330398-F42507CC-5F5D-4CAE-AC4A-E2D46F5FF68AQ37379483-601DA405-0ECD-4096-9AE1-21A7DB34C1ADQ38221645-256EA265-D516-4E16-A662-1A25EC23A592Q38630880-0FE529C5-B6A6-4027-A4F5-1F8C30BCBE68Q38648601-6BDE7729-EF6F-42DB-8E7E-777B71E922F5Q38663764-405975D8-451A-4CA6-9B29-31D847F108CFQ38850249-BCD008D8-136C-4F84-A978-ADC3D257400F
P2860
Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Adverse events associated with ...... atic review and meta-analysis.
@en
type
label
Adverse events associated with ...... atic review and meta-analysis.
@en
prefLabel
Adverse events associated with ...... atic review and meta-analysis.
@en
P2093
P1433
P1476
Adverse events associated with ...... atic review and meta-analysis.
@en
P2093
Edward J Mills
Françoise Renaud-Théry
Isabelle Andrieux-Meyer
Marco Vitoria
Nathan Ford
Nathan Shaffer
Sally Hargreaves
Zara Shubber
P304
P356
10.1097/QAD.0B013E32835F1DB0
P407
P577
2013-06-01T00:00:00Z